Hims & Hers Health’s stock jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded versions of popular GLP-1 drugs.
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
Read Next
- Why Choose Solana for Your Next DeFi Application: A Comprehensive Guide
- SFC issues notices to Interactive Brokers, SBI, Monmonkey, Soochow to freeze certain client accounts
- Private consumption driving growth in Q3 with rural India taking lead: RBI, ET BFSI
- Nvidia (NVDA) stock slumps despite Q3 earnings beat
- India’s consumer durable makers to log 11-12 pc growth in FY25, ET BFSI
- Binance Offers NOTCOIN Red Packet Giveaway via Binance Pay
- Snowflake (SNOW) Q3 earnings report 2025
